Shanghai Fosun Pharmaceutical Files HKEX Return Disclosing Share BuybackPUBT·Nov 18, 2026 at 09:30 AM02196+2.79%600196+0.05%
CMBI Raises SBP GROUP TP to HKD9 as Multiple Innovative Drugs Included in National Medical InsuranceAASTOCKS News·Nov 18, 2026 at 04:23 AM01177-0.82%
BeOne Medicines: Five solid-tumor programs advance as strong cash flow funds continued pipeline investmentQuartr·Nov 17, 2026 at 11:07 AMONC+0.48%06160-1.05%
Simcere Pharmaceutical Files HKEX Next-Day Return Disclosing Share BuybackPUBT·Nov 17, 2026 at 09:31 AM02096-0.76%
Fosun Pharma falls 4% as AR1001 Phase III misses significanceMarket Movers·Nov 17, 2026 at 01:33 AM02196+2.79%
China Adds Record 51 Innovative Drugs to Public Medical Insurance CatalogYicai·Nov 16, 2026 at 11:44 AMAZN-0.95%NVO-2.16%
Fosun Subsidiary Receives Clinical-Trial Approval for FAP PET DrugTip Ranks·Nov 16, 2026 at 10:40 AM02196+2.79%600196+0.05%
BeiGene to Invest $19.5 Million in Bravera’s Series A RoundCoinLive·Nov 16, 2026 at 10:20 AMONC+0.48%06160-1.05%
Fosun Pharma Starts Phase II Trial of FXR0906 for Hypertriglyceridemia in ChinaPUBT·Nov 16, 2026 at 10:03 AM02196+2.79%600196+0.05%
Simcere’s Sanbexin Sublingual Tablets Added to China’s 2026 Reimbursement ListTip Ranks·Nov 15, 2026 at 11:13 PM02096-0.76%
HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List for ELUNATE® and ORPATHYS® | HCM Stock NewsStockTitan·Nov 15, 2026 at 08:00 PMHCM-2.24%HAWG-0.82%
Hengrui Announces Drug Inclusions in China’s 2026 NRDLTip Ranks·Nov 15, 2026 at 11:07 AM01276-2.27%600276-1.59%